|
Name |
4-Oxo-5-phenylpentanoic acid
|
| Molecular Formula | C11H12O3 | |
| IUPAC Name* |
4-oxo-5-phenylpentanoic acid
|
|
| SMILES |
C1=CC=C(C=C1)CC(=O)CCC(=O)O
|
|
| InChI |
InChI=1S/C11H12O3/c12-10(6-7-11(13)14)8-9-4-2-1-3-5-9/h1-5H,6-8H2,(H,13,14)
|
|
| InChIKey |
LTNSOYZGFPWHOF-UHFFFAOYSA-N
|
|
| Synonyms |
4-oxo-5-phenylpentanoic acid; 5-PhenyllevulinicAcid; 3183-15-1; 5-phenyllevulinic acid; 4-oxo-5-phenyl-pentanoic Acid; 5 -phenyllevulinic acid; 4-Oxo-5-phenylvaleric acid; CHEMBL431317; MEGxm0_000067; SCHEMBL2131696; ACon1_000294; CHEBI:183438; ZINC29394259; AKOS004120863; BS-1367; NCGC00180701-01; NCGC00180701-02!4-oxo-5-phenylpentanoic acid; 4-Oxo-5-phenylpentanoic acid, >=90% (LC/MS-UV); BRD-K04362049-001-01-6
|
|
| CAS | NA | |
| PubChem CID | 10375311 | |
| ChEMBL ID | CHEMBL431317 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 192.21 | ALogp: | 1.0 |
| HBD: | 1 | HBA: | 3 |
| Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 54.4 | Aromatic Rings: | 1 |
| Heavy Atoms: | 14 | QED Weighted: | 0.778 |
| Caco-2 Permeability: | -5.273 | MDCK Permeability: | 0.00003500 |
| Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.091 |
| Human Intestinal Absorption (HIA): | 0.012 | 20% Bioavailability (F20%): | 0.004 |
| 30% Bioavailability (F30%): | 0.001 |
| Blood-Brain-Barrier Penetration (BBB): | 0.181 | Plasma Protein Binding (PPB): | 54.47% |
| Volume Distribution (VD): | 0.193 | Fu: | 36.88% |
| CYP1A2-inhibitor: | 0.023 | CYP1A2-substrate: | 0.073 |
| CYP2C19-inhibitor: | 0.022 | CYP2C19-substrate: | 0.063 |
| CYP2C9-inhibitor: | 0.015 | CYP2C9-substrate: | 0.912 |
| CYP2D6-inhibitor: | 0.004 | CYP2D6-substrate: | 0.258 |
| CYP3A4-inhibitor: | 0.006 | CYP3A4-substrate: | 0.121 |
| Clearance (CL): | 7.58 | Half-life (T1/2): | 0.925 |
| hERG Blockers: | 0.02 | Human Hepatotoxicity (H-HT): | 0.243 |
| Drug-inuced Liver Injury (DILI): | 0.913 | AMES Toxicity: | 0.332 |
| Rat Oral Acute Toxicity: | 0.052 | Maximum Recommended Daily Dose: | 0.014 |
| Skin Sensitization: | 0.406 | Carcinogencity: | 0.038 |
| Eye Corrosion: | 0.228 | Eye Irritation: | 0.712 |
| Respiratory Toxicity: | 0.038 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC004716 | ![]() |
1.000 | D07ONP | ![]() |
0.531 | ||
| ENC000054 | ![]() |
0.634 | D0P2GK | ![]() |
0.480 | ||
| ENC000004 | ![]() |
0.628 | D0R1CR | ![]() |
0.469 | ||
| ENC005854 | ![]() |
0.523 | D00DZN | ![]() |
0.462 | ||
| ENC000219 | ![]() |
0.523 | D06LHG | ![]() |
0.453 | ||
| ENC000218 | ![]() |
0.523 | D05OIS | ![]() |
0.442 | ||
| ENC000779 | ![]() |
0.521 | D0Y7ZD | ![]() |
0.409 | ||
| ENC000208 | ![]() |
0.489 | D0O4GY | ![]() |
0.400 | ||
| ENC000717 | ![]() |
0.481 | D0Y7EM | ![]() |
0.393 | ||
| ENC002915 | ![]() |
0.473 | D05OFX | ![]() |
0.391 | ||